Company intelligence / Profile preview

Lidi

Ownership: Private
Development stage: Other

Overview

Lidi is a biotechnology company focused on the discovery and development of novel therapeutic agents, primarily targeting oncology and metabolic diseases. The company leverages its expertise in medicinal chemistry and molecular biology to identify and optimize small molecule candidates. Lidi aims to address significant unmet medical needs through innovative drug design and rigorous preclinical evaluation. Its current pipeline is in the early stages of development, with several programs undergoing lead optimization and characterization.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Lidi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lidi.

Explore the full profile